TG Therapeutics Inc (NASDAQ:TGTX) has a beta value of 2.27 and has seen 0.45 million shares traded in the last trading session. The company, currently valued at $4.37B, closed the last trade at $28.08 per share which meant it gained $0.08 on the day or 0.28% during that session. The TGTX stock price is -31.2% off its 52-week high price of $36.84 and 54.27% above the 52-week low of $12.84. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.97 million shares traded. The 3-month trading volume is 2.90 million shares.
The consensus among analysts is that TG Therapeutics Inc (TGTX) is Buy stock at the moment, with a recommendation rating of 1.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 6 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.08.
TG Therapeutics Inc (NASDAQ:TGTX) trade information
Sporting 0.28% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the TGTX stock price touched $28.08 or saw a rise of 10.57%. Year-to-date, TG Therapeutics Inc shares have moved -6.72%, while the 5-day performance has seen it change -6.72%. Over the past 30 days, the shares of TG Therapeutics Inc (NASDAQ:TGTX) have changed -17.25%. Short interest in the company has seen 27.14 million shares shorted with days to cover at 8.95.
Wall Street analysts have a consensus price target for the stock at $23.75, which means that the shares’ value could drop -18.23% from current levels. The projected low price target is $20.0 while the price target rests at a high of $27.5. In that case, then, we find that the current price level is 2.07% off the targeted high while a plunge would see the stock lose 28.77% from current levels.
TG Therapeutics Inc (TGTX) estimates and forecasts
Figures show that TG Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 36.96% over the past 6 months, with this year growth rate of 100.00%, compared to 17.00% for the industry. Revenue growth from the last financial year stood is estimated to be 41.30%.
8 analysts offering their estimates for the company have set an average revenue estimate of 109.31M for the current quarter. 3 have an estimated revenue figure of 116.61M for the next ending quarter. Year-ago sales stood 43.97M and 63.47M respectively for this quarter and the next, and analysts expect sales will grow by 148.59% for the current quarter and 41.30% for the next.
TGTX Dividends
TG Therapeutics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders
Insiders own 9.50% of the company shares, while shares held by institutions stand at 66.37% with a share float percentage of 73.34%. Investors are also buoyed by the number of investors in a company, with TG Therapeutics Inc having a total of 393.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 13.69 million shares worth more than $243.58 million. As of 2024-06-30, VANGUARD GROUP INC held 9.3645% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 11.39 million shares as of 2024-06-30. The firm’s total holdings are worth over $202.6 million and represent 7.7891% of shares outstanding.
